請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67034
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊偉勛 | |
dc.contributor.author | "Chun-Kai, Chang" | en |
dc.contributor.author | 張鈞鎧 | zh_TW |
dc.date.accessioned | 2021-06-17T01:17:55Z | - |
dc.date.available | 2020-09-12 | |
dc.date.copyright | 2017-09-12 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-14 | |
dc.identifier.citation | Adeniran, A. J., et al. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol. 2011 55(6): 570-575.
Agretti, P., et al. Papillary thyroid cancer in a patient with congenital goitrous hypothyroidism due to a novel deletion in NIS gene. Endocrine. 2016 Oct 54(1): 256-258. Ahn, D., et al. BRAF V600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx. 2012 39(2): 198-203. Al-Rasheed, M. M., et al. The potential role of the sodium iodide symporter gene polymorphism in the development of differentiated thyroid cancer. Gene. 2015 Nov 10 572(2): 163-168. Bae, J. S., et al. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn Pathol. 2016 Feb 09 11: 21. Baloch, Z. W., et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008 Jun 36(6): 425-437. Bastos, A. U., et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol. 2015 Oct 173(4): 525-540. Beadnell, T. C., et al. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther. 2016 Aug 15(8): 1952-1963. Bononi, M., et al. Lymph node dissection in papillary or follicular thyroid carcinoma. Anticancer Res. 2004 Jul-Aug 24(4): 2439-2442. Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014 Oct 23 159(3): 676-690. Cheng, W., et al. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. J Clin Endocrinol Metab. 2016 Mar 101(3): 962-971. Ertorer, M. E., et al. Incidental papillary microcarcinoma of the thyroid. Asian Pac J Cancer Prev. 2007 Oct-Dec 8(4): 631-634. Eszlinger, M., et al. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany. Thyroid. 2017 Mar 27(3): 402-411. Fagin, J. A., et al. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016 Sep 15 375(11): 1054-1067. Feliubadalo, L., et al. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet. 2013 Aug 21(8): 864-870. George, J. R., et al. Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. J Clin Endocrinol Metab. 2015 Dec 100(12): E1550-1559. Haugen, B. R., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan 26(1): 1-133. Hay, I. D., et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993 Dec 114(6): 1050-1057; discussion 1057-1058. Huang, C. J., et al. A systematic review of genetic studies of thyroid disorders in Taiwan. J Chin Med Assoc. 2015 Mar 78(3): 145-153. Ito, Y., et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003 13(4): 381-387. Jin, L., et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget. 2016 Apr 05 7(14): 18346-18355. Jung, C. K., et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012 Aug 22(8): 791-797. Kim, Y. H., et al. Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene. Theranostics. 2015 5(1): 86-96. Kwon, S. M., et al. Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform. 2012 Jun 10(2): 69-73. Ley, P. B., et al. Safety and efficacy of total thyroidectomy for differentiated thyroid carcinoma: a 20-year review. Am Surg. 1993 Feb 59(2): 110-114. Lin, J. D., et al. Diagnosis and therapeutic strategy for papillary thyroid microcarcinoma. Arch Surg. 2005 Oct 140(10): 940-945. Liu, D., et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab. 2007 Jun 92(6): 2264-2271. Liu, R., et al. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016 Mar 23(3): R143-155. Liu, T., et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014 Oct 16 33(42): 4978-4984. Liu, X., et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013 Aug 20(4): 603-610. Lupi, C., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007 Nov 92(11): 4085-4090. Mann, B., et al. Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits? Langenbecks Arch Surg. 1998 Oct 383(5): 355-358. Marchetti, I., et al. Detection of the BRAF V600E mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid. 2012 22(3): 292-298. Mazzaferri, E. L., et al. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001 Apr 86(4): 1447-1463. Melo, M., et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014 May 99(5): E754-765. Moon, W.-J., et al. BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles. American Journal of Roentgenology. 2012 198(3): 668-674. Nasirden, A., et al. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Arch. 2016 Dec 469(6): 687-696. Nikiforov, Y. E., et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014 Dec 01 120(23): 3627-3634. Nikiforov, Y. E., et al. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid. 2015 Nov 25(11): 1217-1223. Nikiforov, Y. E., et al. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011 Aug 30 7(10): 569-580. Nikiforov, Y. E., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009 Jun 94(6): 2092-2098. Nikiforova, M. N., et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013 Nov 98(11): E1852-1860. Onenerk, A. M., et al. Triage of the indeterminate thyroid aspirate: What are the options for the practicing cytopathologist? Cancer. 2017 Jun 125(S6): 477-485. Piscazzi, A., et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012 Jun 97(6): E898-906. Prescott, J. D., et al. The RET oncogene in papillary thyroid carcinoma. Cancer. 2015 Jul 01 121(13): 2137-2146. Qi, M., et al. Morphologic features of carcinomas with recurrent gene fusions. Adv Anat Pathol. 2012 Nov 19(6): 417-424. Riesco-Eizaguirre, G., et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009 Nov 01 69(21): 8317-8325. Rodrigues, A. C., et al. The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. Curr Genomics. 2017 Jun 18(3): 244-254. Romei, C., et al. RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne). 2012 3: 54. Sakorafas, G. H., et al. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev. 2005 Oct 31(6): 423-438. Shah, J. P., et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992 Dec 164(6): 658-661. Shi, X., et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2015 Apr 100(4): E632-637. Shih, S. R., et al. Preoperative prediction of papillary thyroid carcinoma prognosis with the assistance of computerized morphometry of cytology samples obtained by fine-needle aspiration: preliminary report. Head Neck. 2013 Jan 35(1): 28-34. Simpson, W. J., et al. Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. Am J Med. 1987 Sep 83(3): 479-488. Smith, V. E., et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci. 2009 Sep 15 122(Pt 18): 3393-3402. Song, Y. S., et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer. 2016 May 01 122(9): 1370-1379. Sun, J., et al. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS One. 2016 11(4): e0153319. Tavares, C., et al. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. Eur J Endocrinol. 2016 Apr 174(4): R117-126. Tennakoon, T., et al. Values of molecular markers in the differential diagnosis of thyroid abnormalities. J Cancer Res Clin Oncol. 2017 Jun 143(6): 913-931. Tran, B., et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol. 2012 Feb 20 30(6): 647-660. Vinagre, J., et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Archiv. 2014 465(2): 119-133. Watkinson, J. C., et al. The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl Med Commun. 2004 Sep 25(9): 897-900. Wu, C., et al. Molecular profiling of thyroid cancer subtypes using large-scale text mining. BMC medical genomics. 2014 7(3): S3. Xing, M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007 Dec 28(7): 742-762. Xing, M., et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014 Sep 01 32(25): 2718-2726. Yip, L., et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015 Sep 262(3): 519-525; discussion 524-515. Zhang, Q., et al. Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population. Thyroid. 2013 Jan 23(1): 38-44. Zhang, T., et al. An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma. Genes Chromosomes Cancer. 2015 Mar 54(3): 168-176. Ziai, J., et al. BRAF mutation testing in clinical practice. Expert Rev Mol Diagn. 2012 Mar 12(2): 127-138. Zong, C., et al. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science. 2012 Dec 21 338(6114): 1622-1626. Zou, M., et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014 Aug 24(8): 1256-1266. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67034 | - |
dc.description.abstract | 甲狀腺結節有很高的盛行率,其中甲狀腺癌約5%,以乳突癌(papillary thyroid cancer, PTC)與濾泡癌(follicular thyroid cancer, FTC)居多。目前用來診斷甲狀腺結節良惡性的標準方法是細針穿刺細胞學檢查(fine needle aspiration cytology, FNAC),但約有15%的結節無法依此確定良惡性。因此,發展準確診斷FNAC檢體的方法是急迫且重要的臨床問題。
甲狀腺癌的臨床表現和細胞型態都是重要的phenotype,為了促進甲狀腺癌的診斷與預後評估的準確性,本計畫將透過基因體學來研究特定生物標記和甲狀腺癌致病機轉的關係。在基因與臨床表現的研究中,BRAF、RAS等基因突變已明確被發現與甲狀腺癌相關,因為他們的突變會造成MAPK signaling pathway活化,使細胞增生。根據外國文獻,當FNAC無法確診時,基因突變檢測可協助區分良惡性,提升診斷正確性。在其他可能的致病基因清單中,sodium iodide symporter (NIS)是很少被分析但值得進一步研究的基因,因為甲狀腺癌細胞攝取碘的能力與其分化程度及預後相關。本研究使用次世代定序來分析NIS, BRAF, RAS與其他可能之基因突變熱點,探討國人基因變異和疾病診斷、預後相關性以外,同時會更全面性地找尋其它仍未被發現的單點基因突變或其他的基因突變方式。 本計劃的主要目的為結合基因體與細胞形態特徵等方法來分析甲狀腺FNAC檢體,以促進甲狀腺癌的診斷與預後評估的準確性,進一步探討分子生物學的變化,以瞭解其與PTC與FTC之診斷及預後之關係。本研究共收案37位病患,其中包含Group 1— 穿刺細胞學報告為malignant的病人 15位,Group 2— 穿刺細胞學報告為suspicious or indeterminate的病人20位,及Group 3— 穿刺細胞學報告為benign的病人2位。基因檢測結果顯示15個Group1的檢體中全部15個檢體皆檢測出帶有致病的基因變異,陽性率100%。20位Group2的病人中,其中三位開刀的結果是良性增生性結節,這三個穿刺細胞學檢體基因檢測皆未檢出致病的基因變異;其餘17位開刀結果為甲狀腺癌,15位檢測出有致病的基因變異,陽性率88%。而2個Group3的檢體中,一位開刀是良性結節,其檢體並無基因變異;另一位則開刀結果為poorly-differentiated carcinoma,基因檢測出PTEN基因變異。 利用本研究所提出之方法,透過甲狀腺穿刺殘餘之檢體,藉由whole genome amplification可獲得適當量之DNA進行次世代定序,減少病人必須額外接受穿刺之風險。此外本實驗設計次世代定序平台可大規模的檢測26個與甲狀腺癌相關的基因之變異及23種fusion gene,透過一次性的次世代定序結果,能夠同時判讀點突變、小片段缺失、及rearrangement之變異,藉由phenotypes與genotype的對照比較,預期將增進FNAC的診斷正確性和預後評估,並進一步對甲狀腺癌的致病機轉深入了解,以作為將來發展新治療的基礎。 | zh_TW |
dc.description.abstract | The prevalence of thyroid nodules is high and five to fifteen percent of these nodules are malignant; most of them are well-differentiated thyroid cancer, including papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). The current standard diagnostic tool is fine needle aspiration cytological (FNAC) examination of the nodules. The overall sensitivity and specificity is only about 90%, and 15% of the nodules evaluated by FNAC are indeterminate. All of the obstacles become a thorny problem for both healthcare-givers and patients.
The goal of this study is to propose a reliable method for diagnosis and prognosis of papillary thyroid cancer and follicular thyroid cancer through analyzing genetic mutations and cellular morphologic characteristics. Clinical presentation and cellular morphology are all important phenotypes of thyroid cancer. To improve the diagnostic and prognosis prediction, this project integrates genomic approaches to establish a causal link between selected biomarkers and disease pathogenesis. We enrolled the patients aged 20 to 85 years old who received FNAC in NTUH. According to cytology results, we classified subjects into three groups, including Group1 - malignant, Group2 – Indeterminate, and Group3 – Benign. The remaining material in the two FNA needles was collected and whole genome amplified afterward. We studied genetic variants through next-generation sequencing of a tailored panel consisting of 26 genes and 23 genetic fusions. In summary, this study applies a multi- and inter-disciplinary approach to improve the accuracy and sensitivity for diagnosis and prognosis of thyroid cancer using FNAC specimens. We have analyzed 37 samples including 15 subjects in Group1, 20 subjects in Group2, and 2 subjects in Group3. We found pathogenic variants in all Group1 samples (positive rate 100%) and 15 pathology-proved malignant Group2 samples (positive rate 88%). The most common variant is BRAFV600E, 7 in Group1 and 10 in Group2. Genetic fusion of NCOA4/RET, RBPMS/NTRK3, and CCDC6/RET can be detected via our DNA-based method. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:17:55Z (GMT). No. of bitstreams: 1 ntu-106-P04421015-1.pdf: 1456360 bytes, checksum: e9a9c321ee978c3e7574d0f19e92c957 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書………………………………………………………………… i
誌謝………………………………………………………………………………… ii 中文摘要…………………………………………………………………………… iii 英文摘要…………………………………………………………………………… v 碩士論文內容 第一章 緒論………………………………………………………………….. 1 第二章 研究方法與材料………………………………………………………… 5 2.1受試者選擇…………………………………………………………………… 5 2.2甲狀腺細針穿刺及細胞學結果判讀………………………………………… 5 2.3甲狀腺穿刺細胞基因檢測…………………………………………………… 5 2.4次世代定序…………………………………………………………………… 5 2.5資料分析與結果統計………………………………………………………… 5 第三章 結果………………………………………………………………………. 7 第四章 討論……………………………………………………………………… 8 第五章 展望……………………………………………………………………... 11 第六章 論文英文簡述………………………………………………………… 12 參考文獻…………………………………………………………………………… 14 表1………………………………………………………………………………….. 22 表2………………………………………………………………………………….. 22 圖1………………………………………………………………………………….. 23 圖2………………………………………………………………………………….. 24 圖3………………………………………………………………………………….. 25 圖4………………………………………………………………………………….. 26 | |
dc.language.iso | zh-TW | |
dc.title | 台灣地區甲狀腺癌之基因研究 | zh_TW |
dc.title | Genetic Analysis of Thyroid Cancer in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳沛隆 | |
dc.contributor.oralexamcommittee | 施翔蓉 | |
dc.subject.keyword | 甲狀腺結節,甲狀腺癌,基因體,甲狀腺細胞穿刺,次世代定序, | zh_TW |
dc.subject.keyword | thyroid nodules,thyroid carcinoma,genomics,fine needle aspiration cytology,next-generation sequencing, | en |
dc.relation.page | 26 | |
dc.identifier.doi | 10.6342/NTU201702918 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 1.42 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。